Pharmaceutical Distribution Partner for API and Raw Material Suppliers

Pharmaceutical Distribution — A Structured Commercial Partner for Suppliers Entering Asian Markets

If you manufacture APIs, pharmaceutical raw materials, finished pharmaceutical goods, or allied healthcare products, your commercial growth depends on reaching the right buyers in the right markets with a trading structure that works cleanly on both sides of the transaction.

Building direct buyer relationships across South Asia and Southeast Asia takes time, resource, and a level of local market knowledge that most manufacturers outside those regions do not have readily available. Regulatory differences, payment system complexity, language barriers, and the administrative weight of managing multiple cross-border buyer accounts can make direct market entry slower and more expensive than it needs to be.

Equihealth FZCO is a pharmaceutical distribution partner based in Dubai Commercity, UAE. We work with API manufacturers and raw material suppliers in India, China, and Europe who want structured, commercially sound access to pharmaceutical buyers across Asia. We manage the commercial relationship, the documentation, and the payment on your behalf — through our Bill-to Ship-to trading model.

What Equihealth Offers Suppliers

Direct buyer relationships across eleven markets.

Equihealth's target buyer network spans Bangladesh, Pakistan, Singapore, Indonesia, Vietnam, Malaysia, Thailand, Hong Kong, China, India, and Egypt — some of the most active generic pharmaceutical formulation economies in the world. Reaching them through Equihealth means accessing an existing commercial network rather than building one from scratch.

A professionally structured commercial counterparty.

When you work with Equihealth, your commercial relationship is with a single, professionally managed trading company incorporated in Dubai Commercity, UAE. You issue one invoice. You manage one payment relationship. You deal with one counterparty who takes responsibility for the buyer side of the transaction.

UAE banking infrastructure supporting payment reliability.

Equihealth maintains banking relationships with established financial institutions in the UAE. These relationships support standard trade finance instruments, including letters of credit and documentary collections. For suppliers who need confidence that payment commitments will be met, Equihealth's financial standing and banking infrastructure provide that assurance.

Fast decision-making and direct communication.

Equihealth operates with a lean structure designed for commercial speed. Enquiries are responded to promptly. Commercial terms are discussed directly. Decisions are made without the layers of approval that slow larger organisations down.

Access to professional advisory support.

Equihealth works with specialist consultants across pharmaceuticals, chemicals, supply chain management, and regulatory affairs. Suppliers who need technical or regulatory guidance as part of a trading relationship can access this expertise through Equihealth's professional network.

How the Trading Relationship Works for Suppliers

Your invoice goes to Equihealth. You ship directly to the end buyer — Equihealth provides the ship-to details. Equihealth manages the buyer relationship separately. You settle with Equihealth on agreed terms using UAE banking infrastructure. The mechanism — wire transfer, letter of credit, or other trade finance instrument — is agreed based on the nature of the transaction and the preferences of both parties.
How the Bill-to Ship-to Model Works

Who Equihealth Is Looking to Work With

API Manufacturers

Producers of bulk active pharmaceutical ingredients in India, China, or the EU whose products meet GMP requirements and whose documentation standards align with the requirements of pharmaceutical buyers in South and Southeast Asia.

Pharmaceutical Raw Material Producers

Manufacturers of excipients, solvents, binders, coating agents, and other pharmaceutical-grade raw materials. The documentation standard we require is the same as for APIs: accurate Certificate of Analysis, batch traceability, and specification consistency.

Finished Pharmaceutical Goods Manufacturers

Producers of finished dosage forms — tablets, capsules, injectables, liquids, and topical preparations — looking for commercial distribution into Asian markets through a structured trading intermediary.

Para-Pharmaceutical and Cosmetic Manufacturers

Producers of OTC health products, nutritional supplements, cosmetic raw materials, and finished personal care goods whose products meet the regulatory requirements of our target markets.

Surgical and Medical Diagnostic Equipment Manufacturers

Producers of medical devices and diagnostic equipment carrying the appropriate CE marking or equivalent certification whose products meet the applicable regulatory requirements in our target destination markets.

Industrial Chemical Manufacturers

Producers of industrial-grade chemicals used in pharmaceutical manufacturing and allied processing industries, handled within applicable export control and trade compliance requirements.

Why Dubai Makes This Relationship Work for Suppliers

Suppliers in India and China already understand Dubai as a pharmaceutical trade hub. UAE-based trading companies are familiar counterparties for manufacturers in those markets, and the commercial and banking infrastructure supporting trade between India, China, and the UAE is well established.
For European suppliers, Dubai provides a commercially sound entry point into Asian pharmaceutical markets — rather than building direct relationships across multiple Asian jurisdictions, each with their own regulatory framework, payment system, and language. Equihealth's position in Dubai Commercity adds institutional credibility: transparent corporate structure, disclosed ownership, and compliance aligned with UAE regulatory requirements and international trade standards.
Why Dubai and UAE

The Supplier Conversation — Where to Start

Tell us what you manufacture, which markets you are trying to reach, and what a workable trading arrangement looks like from your side. We will tell you whether there is a fit with Equihealth's buyer network and what the next steps look like. No lengthy registration processes before an initial conversation.
Contact Equihealth
Markets We Serve

Frequently Asked Questions

Equihealth works with manufacturers of APIs, pharmaceutical raw materials, finished pharmaceutical goods, para-pharmaceutical products, cosmetic and personal care items, surgical and medical diagnostic equipment, and industrial chemicals. Suppliers should be established manufacturers with appropriate quality documentation and the ability to supply to the specifications required by pharmaceutical buyers in Asian markets.
No. Equihealth does not require exclusive supply arrangements. Suppliers are free to maintain their own direct buyer relationships and relationships with other trading partners alongside their relationship with Equihealth.
Yes. Working with Equihealth does not require you to restructure your existing direct relationships. We add commercial coverage in markets or with buyers you are not currently reaching directly, without requiring exclusivity or changes to your existing trading arrangements.
We do not have a published minimum volume requirement. Commercial terms, including minimum transaction sizes, are discussed on a case-by-case basis. Contact us with your product and volume details and we will give you a direct answer.